Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: a retrospective analysis of the EBMT Chronic Malignancies working party of the EBMT. Y. Chalandon et al. EBMT 2018 presentations from the MDS subcommittee

**Results**

- An initiative to refine and update the general international guidelines for patients with MDS and to evaluate the impact of alloHSCT for potential candidates for HSCT.
- Using the information from the general MDS guidelines, an expert task force developed HSCT scenarios for patients with MDS, which were evaluated and discussed by a panel of experts during several consensus meetings. T. de Witte et al.

**Recently accepted in JCO (35:2157)**

Dose-reduced vs. standard conditioning followed by allogeneic stem cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase III study of the EBMT (RICMAC Trial). N. Kröger et al.

**EBMT 2018 presentations from the MDS subcommittee**

- Molecular genetics and transplant outcome in MDS
  - Marie Robin, Monday March 19th, CMWP session, 09:00-09:30, Room 3A
- Long term outcome of patients with MDS surviving allogeneic stem cell transplantation
  - Johannes Schetelig, Monday March 19th, CMWP session, 10:10-10:30, Room 3A
- Transplant-specific EBMT scoring system improves prognostic capability in myelodysplastic syndromes after allogeneic stem-cell transplantation
  - Nico Gagelmann et al., Monday March 19th, 17:10-17:20, Room 3B
- Comparison of sequential versus myeloablative, reduced intensity and non-myeloablative conditioning for patients with myelodysplastic syndrome
  - Victoria Potter et al., Tuesday March 20th, 17:20-17:30, Auditorium VI
- Comparative outcomes for matched and mismatched (haplo) family donors for myelodysplastic syndromes
  - Kovita Rai et al., Wednesday March 21st, 11:20-11:30, Auditorium III

**Posters**

- Tuesday March 20th, Poster Area
  - Poster B243: External validation of scores predicting non-relapse mortality in patients with myelodysplastic syndrome. Martin Carre et al.
  - Poster B244: Impact of in-vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic HSCT. Edouard Forcaët et al.

**Other papers recently published (2017)**